Hidenori Toyoda

Ogaki, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 540 publications

Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 29, 2026

Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline-A Step Towards Functional Cure or a Marginal Margin? Authors' Reply.

Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline-A Step Towards Functional Cure or a Marginal Margin? Authors' Reply.

Journal: Alimentary pharmacology & therapeutics

Published: May 15, 2026

Letter: Does Serum HBV RNA Add Incremental Value for Hepatocellular Carcinoma Risk Stratification Beyond Established Predictors? Authors' Reply.

Letter: Does Serum HBV RNA Add Incremental Value for Hepatocellular Carcinoma Risk Stratification Beyond Established Predictors? Authors' Reply.

Journal: Alimentary pharmacology & therapeutics

Published: May 01, 2026

Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

Journal: Oncology

Published: April 19, 2026

Did the COVID-19 pandemic disrupt the continuity of post-SVR surveillance in HCV-cured patients?

Did the COVID-19 pandemic disrupt the continuity of post-SVR surveillance in HCV-cured patients?

Journal: Journal of gastroenterology

Published: April 15, 2026

Phylodynamics and Molecular Evolution of Hepatitis A Virus During the Years 1957-2021 in Japan.

Phylodynamics and Molecular Evolution of Hepatitis A Virus During the Years 1957-2021 in Japan.

Journal: Journal of medical virology

Published: April 10, 2026

Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: April 07, 2026

Validation of Risk Models for Predicting Post-SVR HCC in Real-World Surveillance Across Global Geographic Regions.

Validation of Risk Models for Predicting Post-SVR HCC in Real-World Surveillance Across Global Geographic Regions.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: April 05, 2026

Identifying a biologically high-risk subgroup of anatomically resectable hepatocellular carcinoma.

Identifying a biologically high-risk subgroup of anatomically resectable hepatocellular carcinoma.

Journal: Hepatology international

Published: March 22, 2026

Quantitative ultrasound attenuation imaging outperforms B-mode scoring for assessing hepatic steatosis.

Quantitative ultrasound attenuation imaging outperforms B-mode scoring for assessing hepatic steatosis.

Journal: Ultrasonography (Seoul, Korea)

Published: March 19, 2026

Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma.

Ablation-Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular Carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: March 17, 2026

Impact of TOPAZ-1 eligibility on the survival benefit of durvalumab plus gemcitabine-cisplatin in advanced biliary tract cancer: a multicenter real-world study.

Impact of TOPAZ-1 eligibility on the survival benefit of durvalumab plus gemcitabine-cisplatin in advanced biliary tract cancer: a multicenter real-world study.

Journal: Journal of gastroenterology

Published: February 20, 2026

Showing 1-12 of 540

Last Updated: 09/26/2026